Sanctuary Advisors LLC Buys Shares of 53,893 Genmab A/S (NASDAQ:GMAB)

Sanctuary Advisors LLC acquired a new stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 53,893 shares of the company's stock, valued at approximately $1,354,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of GMAB. Capital International Investors lifted its position in Genmab A/S by 7.8% during the first quarter. Capital International Investors now owns 4,373,277 shares of the company's stock valued at $130,805,000 after acquiring an additional 315,355 shares during the last quarter. Harding Loevner LP grew its stake in Genmab A/S by 2.7% during the 4th quarter. Harding Loevner LP now owns 3,289,895 shares of the company's stock worth $97,569,000 after buying an additional 85,665 shares during the last quarter. Renaissance Technologies LLC increased its position in Genmab A/S by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company's stock valued at $36,752,000 after buying an additional 103,859 shares in the last quarter. DDD Partners LLC acquired a new stake in Genmab A/S in the second quarter worth about $8,860,000. Finally, Cubist Systematic Strategies LLC grew its stake in shares of Genmab A/S by 109.7% during the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company's stock worth $7,000,000 after acquiring an additional 145,689 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on GMAB. Morgan Stanley restated an "equal weight" rating and set a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. Royal Bank of Canada raised Genmab A/S from a "sector perform" rating to an "outperform" rating in a report on Monday, July 15th. Truist Financial reduced their price target on shares of Genmab A/S from $53.00 to $50.00 and set a "buy" rating for the company in a research report on Monday, September 9th. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Friday, September 20th. Finally, Redburn Atlantic started coverage on Genmab A/S in a research note on Tuesday. They set a "buy" rating for the company. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $45.20.

Genmab A/S Stock Performance

Shares of GMAB traded down $0.18 during trading hours on Friday, hitting $23.53. 2,007,818 shares of the stock were exchanged, compared to its average volume of 592,568. The stock's 50-day moving average price is $26.17 and its two-hundred day moving average price is $27.39. Genmab A/S has a 12-month low of $23.24 and a 12-month high of $33.60. The company has a market cap of $15.57 billion, a price-to-earnings ratio of 19.45, a price-to-earnings-growth ratio of 0.71 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The business had revenue of $779.50 million during the quarter, compared to analysts' expectations of $734.60 million. On average, research analysts expect that Genmab A/S will post 1.27 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.